Welcome to Startups Weekly — your weekly recap of everything you can't miss from the world of startups. Want it in your inbox ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

NewLimit was founded to develop medicines that add healthy years to each human life. Initially, we thought it would take many ...

NewLimit’s Series B raise adds fuel to Silicon Valley’s growing obsession with anti-aging science and biohacking immortality.

NewLimit, a startup that aims to increase how long people can live a healthy life by genetically programming their cells, has ...

On Tuesday, that startup— NewLimit —raised a $130 million Series B round led by venture capital giant Kleiner Perkins with ...

Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a ...

NewLimit raises $130M Series B led by Kleiner Perkins to advance epigenetic reprogramming research for liver disease treatment, with backing from Coinbase CEO Brian Armstrong.

Beyond analysts' top -and-bottom-line estimates for Coinbase Global (COIN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the ...

Marina Temkin is a venture capital and startups reporter at TechCrunch. Prior to joining TechCrunch, she wrote about VC for PitchBook and Venture Capital Journal. Earlier in her career, Marina was ...